Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Esophageal Neoplasms 12Esophageal Squamous Cell Carcinoma 11Pancreatic Neoplasms 8Stomach Neoplasms 4Colorectal Neoplasms 3Pancreatic cancer, adult 2Squamous Cell Carcinoma of Anal Canal 1Resectable Pancreatic Cancer 1Pancreatic Cancer Resectable 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer 1Esophageal 1Advanced Pancreatic Cancer 1Advanced Esophageal 1Advanced Colorectal Cancer 1Adenocarcinoma 1

Interventions

Gemcitabine 5130-nm albumin-bound paclitaxel 3nimotuzumab 2Oxaliplatin 2Leucovorin 2Irinotecan 2Hematologic Tests 2Fluorouracil 2Albumin-Bound Paclitaxel 2surufatinib 1napabucasin 1irinotecan sucrosofate 1ensituximab 1Taxes 1S 1 (combination) 1Radiofrequency Ablation 1Paclitaxel 1Mass Screening 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic cancer, adult × nimotuzumab × Gastrointestinal × Clear all
NCT07277452 2025-12-11

NOTABLE-309

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
156 enrolled
Gastrointestinal

Pancreatic cancer, adult

NCT06938503 2025-04-22

AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
48 enrolled
Gastrointestinal

Pancreatic cancer, adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡